The Europe clinical trials market size is expected to reach USD 20.2 billion by 2030. The market is expected to expand at a CAGR of 5.7% from 2022 to 2030. The rise in technological advancement for clinical trials is one of the key factors driving the market. The growing adoption of new technologies like artificial intelligence, big data analytics, blockchain, clinical trials payments, and patient engagement solutions among others have significantly contributed to the market growth. The COVID-19 pandemic had improved the adoption of virtual clinical trials in the region. Therefore, the growing adoption of new technologies is likely to promote the growth of the market.
The demand for personalized medicines has significantly improved in the region owing to significant research funding for personalized therapies by the European Commission. The aim of various countries in Europe is to collaborate research and health policy to accelerate the adoption of personalized medicine with the formation of the International Consortium for Personalized Medicine, which brings together health research funders and policymaking groups. Such activities are likely to promote market growth. The region suffers from growing disease variation and prevalence. A significant number of people in the region suffer from chronic and rare diseases.
For instance, the European Commission states that approximately 5,000-8,000 distinct rare diseases affect around 6-8% of the European population i.e., between 27 - 36 million. Thus, the high burden of rare diseases is likely to increase the demand for researchers to develop therapeutics for rare diseases. The rising cost associated with research studies has increased the demand for CROs in the region for conducting clinical trials. The partnership agreement between pharmaceutical companies and CROs is likely to promote market growth.
Europe was one the worst affected region by the COVID-19 pandemic, owing to which public organizations in the region made significant funding in research to boost the development of COVID-19 vaccines and diagnostics. For instance, in June 2020 the French president pledged to invest USD 679 million to support the development of COVID-19 vaccines. Owing to the pandemic several research centers were shut down due to the national lockdown implemented by the government authorities, owing to which several clinical trial organizations opted for in silico trials and virtual clinical trials to speed up the research process. Such actions had profited the growth of the market.
This product will be delivered within 1-3 business days.
The demand for personalized medicines has significantly improved in the region owing to significant research funding for personalized therapies by the European Commission. The aim of various countries in Europe is to collaborate research and health policy to accelerate the adoption of personalized medicine with the formation of the International Consortium for Personalized Medicine, which brings together health research funders and policymaking groups. Such activities are likely to promote market growth. The region suffers from growing disease variation and prevalence. A significant number of people in the region suffer from chronic and rare diseases.
For instance, the European Commission states that approximately 5,000-8,000 distinct rare diseases affect around 6-8% of the European population i.e., between 27 - 36 million. Thus, the high burden of rare diseases is likely to increase the demand for researchers to develop therapeutics for rare diseases. The rising cost associated with research studies has increased the demand for CROs in the region for conducting clinical trials. The partnership agreement between pharmaceutical companies and CROs is likely to promote market growth.
Europe was one the worst affected region by the COVID-19 pandemic, owing to which public organizations in the region made significant funding in research to boost the development of COVID-19 vaccines and diagnostics. For instance, in June 2020 the French president pledged to invest USD 679 million to support the development of COVID-19 vaccines. Owing to the pandemic several research centers were shut down due to the national lockdown implemented by the government authorities, owing to which several clinical trial organizations opted for in silico trials and virtual clinical trials to speed up the research process. Such actions had profited the growth of the market.
Europe Clinical Trials Market Report Highlights
- The phase I trial segment is projected to witness a remarkable growth rate of 6.1% over the forecast period. This can be attributed to the significant R&D spending by public and private organizations to support new researches
- The interventional study design segment held the largest market share of 78.6% in 2021 owing to the greater accuracy offered by these studies, as compared to other clinical study designs
- European countries such as Germany and the U.K. are spearheading the revenue share, as these have a large patient pool and the presence of advanced medical infrastructure
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Europe Clinical Trials Market: Variables, Trends & Scope
Chapter 4 Europe clinical trials Market: Study Design Segment Analysis
Chapter 5 Europe clinical trials Market: Phase Segment Analysis
Chapter 6 Europe Clinical Trials Market: Country Analysis
Chapter 7 Company Profiles
List of Tables
List of Figures
Companies Mentioned
- IQVIA Holdings, Inc.,
- Parexel International Corporation
- PPD, Inc.
- Syneos Health
- Eli Lilly and Company
- Novo Nordisk A/S
- Pfizer, Inc.
- Dr. Notghi Contract Research GmbH
- Charite Research Organisation GmbH
- Janssen Global Services, LLC
- KFGN
- Clariness
- Invisio Clinical Studies Consulting GmbH
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 114 |
| Published | March 2022 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 12.9 Billion |
| Forecasted Market Value ( USD | $ 20.2 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 13 |
